Portions of this material were presented in abstract form to the 30th Annual Conference of the Veterinary Cancer Society, San Diego, CA, October 2010.
Multicenter Prospective Trial of Hypofractionated Radiation Treatment, Toceranib, and Prednisone for Measurable Canine Mast Cell Tumors
Version of Record online: 19 DEC 2011
Copyright © 2011 by the American College of Veterinary Internal Medicine
Journal of Veterinary Internal Medicine
Volume 26, Issue 1, pages 135–141, January-February 2012
How to Cite
Carlsten, K.S., London, C.A., Haney, S., Burnett, R., Avery, A.C. and Thamm, D.H. (2012), Multicenter Prospective Trial of Hypofractionated Radiation Treatment, Toceranib, and Prednisone for Measurable Canine Mast Cell Tumors. Journal of Veterinary Internal Medicine, 26: 135–141. doi: 10.1111/j.1939-1676.2011.00851.x
- Issue online: 10 JAN 2012
- Version of Record online: 19 DEC 2011
- Manuscript Accepted: 10 NOV 2011
- Manuscript Revised: 18 OCT 2011
- Manuscript Received: 24 AUG 2011
- Pfizer Animal Health provided
Mast cell tumors (MCT) are common cutaneous tumors in dogs and when not amenable to surgical excision can present a therapeutic challenge. New treatment protocols for unresectable MCT are needed.
The combination of toceranib, prednisone, and hypofractionated radiation treatment (RT) will be well tolerated and efficacious.
Seventeen client-owned dogs with measurable MCT amenable to RT.
Prospective clinical trial. All dogs received prednisone, omeprazole, diphenhydramine, and toceranib. Toceranib was administered for 1 week before initiating RT, consisting of 24 Gy delivered in 3 or 4 fractions.
On an intent-to-treat basis, the overall response rate was 76.4%, with 58.8% of dogs achieving a complete response and 17.6% a partial response. The median time to best response was 32 days, and the median progression-free interval was 316 days. The overall median survival time was not reached with a median follow-up of 374 days. The most common toxicoses were gastrointestinal and hepatic.
Conclusions and Clinical Importance
The combination of hypofractionated RT, toceranib, and prednisone was tolerated and efficacious in the majority of dogs. Response rates and durations were higher than those reported for toceranib as a single-agent treatment for MCT. This combination is a viable treatment option for unresectable MCT.